Original Investigation

Human Genetics

, Volume 123, Issue 1, pp 65-75

First online:

Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb

  • Bo JohannesonAffiliated withCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health
  • , Shannon K. McDonnellAffiliated withDepartment of Health Sciences Research, Mayo Clinic
  • , Danielle M. KaryadiAffiliated withCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health
  • , Scott J. HebbringAffiliated withDepartment of Laboratory Medicine and Pathology, Mayo Clinic
  • , Liang WangAffiliated withDepartment of Laboratory Medicine and Pathology, Mayo Clinic
  • , Kerry DeutschAffiliated withInstitute for Systems Biology
  • , Laura McIntoshAffiliated withDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center
  • , Erika M. KwonAffiliated withCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health
  • , Miia SuuriniemiAffiliated withCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health
    • , Janet L. StanfordAffiliated withDivision of Public Health Sciences, Fred Hutchinson Cancer Research CenterDepartment of Epidemiology, School of Public Health and Community Medicine, University of Washington
    • , Daniel J. SchaidAffiliated withDepartment of Health Sciences Research, Mayo Clinic
    • , Elaine A. OstranderAffiliated withCancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health
    • , Stephen N. ThibodeauAffiliated withDepartment of Laboratory Medicine and Pathology, Mayo Clinic Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Genetic studies suggest that hereditary prostate cancer is a genetically heterogeneous disease with multiple contributing loci. Studies of high-risk prostate cancer families selected for aggressive disease, analysis of large multigenerational families, and a meta-analysis from the International Consortium for Prostate Cancer Genetics (ICPCG), all highlight chromosome 22q12.3 as a susceptibility locus with strong statistical significance. Recently, two publications have narrowed the 22q12.3 locus to a 2.18 Mb interval using 54 high-risk families from the ICPCG collaboration, as defined by three recombination events on either side of the locus. In this paper, we present the results from fine mapping studies at 22q12.3 using both haplotype and recombination data from 42 high-risk families contributed from the Mayo Clinic and the Prostate Cancer Genetic Research Study (PROGRESS) mapping studies. No clear consensus interval is present when all families are used. However, in the subset of 14 families with ≥5 affected men per family, a 2.53-Mb shared consensus segment that overlaps with the previously published interval is identified. Combining these results with data from the earlier ICPCG study reduces the three-recombination interval at 22q12.3 to approximately 1.36 Mb.